Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria

CompletedOBSERVATIONAL
Enrollment

108

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Non-Small-Cell Lung CancerBreast Cancer
Interventions
DRUG

Vinorelbine oral

Trial Locations (56)

Unknown

Braunau am Inn

Graz

Innsbruck

Klagenfurt

Vienna

Villach

Vöcklabruck

Aachen

Altötting

Amberg

Bad Nauheim

Ballenstedt

Berlin

Bielefeld

Chemnitz

Cologne

Dessau

Donauwörth

Eggenfelden

Erbach im Odenwald

Erfurt

Frankfurt am Main

Göppingen

Greifswald

Güstrow

Halle

Hanover

Heppenheim an der Bergstrasse

Homburg

Karlsruhe

Kiel

Kulmbach

Lich

Lostau

Ludwigsburg

Lübeck

Mainz

Mannheim

Marktredwitz

Memmingen

Munich

Münster

Offenbach

Offenburg

Ostfildern

Regensburg

Saarbrücken

Schwandorf in Bayern

Solingen

Stolberg

Villingen-Schwenningen

Waltershausen

Weinheim

Werdau

Wesel

Winnenden

All Listed Sponsors
collaborator

Winicker Norimed GmbH

INDUSTRY

lead

Pierre Fabre Pharma GmbH

INDUSTRY

NCT02619929 - Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria | Biotech Hunter | Biotech Hunter